GENEVA, December 21, 2010 /PRNewswire/ -- Merck Serono, the pharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced a strategic agreement with Philochem AG, Switzerland, the research unit of Philogen S.p.A., Italy. Under the terms of the agreement, Philochem will supply specific monoclonal antibodies to Merck Serono, to be used in the search for molecular biomarkers of oocyte and embryo quality. Further terms of the agreement are not disclosed.

Once validated, molecular biomarkers can be used for the development of predictive or diagnostic tests that can help physicians assess objectively oocyte and embryo quality.

"We are convinced that the development of innovative non-invasive diagnostic tests to evaluate oocyte and embryo quality could help In Vitro Fertilization specialists offer infertile couples the best chance of achieving their dream of having a baby on their own," said Bernhard Kirschbaum, Executive Vice President, Head of Global Research and Development at Merck Serono.

"Philochem has a considerable track record in the isolation of specific binding molecules. We are delighted to enter into this collaborative agreement with Merck Serono in the area of fertility and we look forward to contributing to the advancement of In Vitro Fertilization techniques," said Dr. Eveline Trachsel, Director of Research, at Philochem AG.

Merck Serono is the world leader in fertility treatments. The company's vision is to develop and provide innovative, easy-to-use products and devices, as well as new technologies to help infertile couples at every stage of the reproductive cycle: from follicular development to early pregnancy.